Current aspects in pharmacology of modified hemoglobins

Advanced Drug Delivery Reviews

Volumn 40, Issue 3, 2000, Pages 185-198

  Palaparthy, Rameshraja ^a   Wang, Huashan ^a   Gulati, Anil ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Blood substitutes; Clinical status; Emergency medicine; Hemoglobin; Oxygen therapeutics; Transfusion

Indexed keywords

BLOOD SUBSTITUTES; CELLS; CONTROLLED DRUG DELIVERY; HYDROCARBONS; ONCOLOGY; PHARMACOKINETICS; PULMONARY DISEASES; SURGERY;

OXYGEN THERAPEUTICS; PERFLUOROCARBONS; RED BLOOD CELLS; TRANSFUSION;

HEMOGLOBIN;

BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN DERIVATIVE; POLYMERIZED HEMOGLOBIN; PYRIDOXYLHEMOGLOBIN; PYRIDOXYLPOLYHEMOGLOBIN; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

BLEEDING; BLOOD TRANSFUSION; BYPASS SURGERY; ELECTIVE SURGERY; HUMAN; HYPERTENSION; HYPOTENSION; INJURY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIOSENSITIZATION; REVIEW; TISSUE OXYGENATION;

EID: 0342980854     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00049-6     Document Type: Article

References (91)

1. Hess J.R., Winslow R.M. Red cell substitutes. Anderson K.C., Ness P.M. Scientific Basis of Transfusion Medicine. 1994;815-829 Saunders, Philadelphia, PA.
2. Williams M.J. Blood substitutes for transfusion. Tech. Urol. 2:1996;179-186.
3. Winslow R.M. Blood substitutes - a moving target. Nat. Med. 1:1995;1212-1215.
4. Winslow R.M. Blood substitutes in development. Expert Opin. Invest. Drugs. 5:1996;1443-1452.
5. Hess J.R. Blood substitutes. Semin. Hematol. 33:1996;369-378.
6. Dietz N.M., Joyner M.J., Warner M.A. Blood substitutes: fluids, drugs, or miracle solutions? Anesth. Analg. 82:1996;390-405.
7. Winslow R.M. Potential clinical applications for blood substitutes. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;205-217.
8. Bunn H.F. The role of hemoglobin based blood substitutes in transfusion medicine. Transfus. Clin. Biol. 2:1995;433-439.
9. Jones J.W., Rogers E. Artificial blood substitutes. Crna. 3:1992;104-108.
10. Odling-Smee W. ABC of transfusion. Red cell substitutes. BMJ. 300:1990;599-601.
11. Lutz J., Barthel U., Metzenauer P. Variation in toxicity of Escherichia coli endotoxin after treatment with perfluorated blood substitutes in mice. Circ. Shock. 9:1982;99-106.
12. Chatterjee R., Welty E.V., Walder R.Y., Pruitt S.L., Rogers P.H., Arnone A., Walder J.A. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1-lysine 99 alpha 2). J. Biol. Chem. 261:1986;9929-9937.
13. Gulati A., Sharma A.C., Burhop K.E. Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglobin on the regional circulation and systemic hemodynamics. Life Sci. 55:1994;827-837.
14. Sharma A.C., Gulati A. Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic hemodynamics and regional circulation in rats. J. Lab. Clin. Med. 123:1994;299-308.
15. Barve A., Sen A.P., Saxena P.R., Gulati A. Dose response effect of diaspirin crosslinked hemoglobin (DCLHb) on systemic hemodynamics and regional blood circulation in rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:1997;75-84.
16. Malcolm D.S., Hamilton I.N. Jr., Schultz S.C., Cole F., Burhop K. Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;91-107.
17. Sen A.P., Dong Y., Saxena P.R., Gulati A. Modulation of resuscitative effect of diaspirin cross-linked hemoglobin by L-NAME in rats. Shock. 9:1998;223-230.
18. Chyu K.Y., Guth P.H., Ross G. Effect of N omega-nitro-L-arginine methyl ester on arterial pressure and on vasodilator and vasoconstrictor responses: influence of initial vascular tone. Eur. J. Pharmacol. 212:1992;159-164.
19. Moisan S., Drapeau G., Burhop K.E., Rioux F. Mechanism of the acute pressor effect and bradycardia elicited by diaspirin crosslinked hemoglobin in anesthetized rats. Can. J. Physiol. Pharmacol. 76:1998;434-442.
20. Gulati A., Rebello S. Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. J. Lab. Clin. Med. 124:1994;125-133.
21. Bilello K., Schultz S., Powell C., Jaffin J., Cole F., Malcolm D. Diaspirin crosslinked hemoglobin (DCLHb): control of pressor effect with anti-hypertensive agents. Artif. Cells Blood Substit. Immobil. Biotechnol. 22:1994;819-825.
22. Sharma A.C., Gulati A. Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic hemodynamics and regional circulatory effects. Crit. Care Med. 23:1995;874-884.
23. Flint L.M., Cryer H.M., Simpson C.J., Harris P.D. Microcirculatory norepinephrine constrictor response in hemorrhagic shock. Surgery. 96:1984;240-247.
24. Hutchins P.M., Goldstone J., Wells R. Effects of hemorrhagic shock on the microvasculature of skeletal muscle. Microvasc. Res. 5:1973;131-140.
25. Gulati A., Sen A.P., Sharma A.C., Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat. Am. J. Physiol. 273:1997;H827-H836.
26. Moo-Penn W.F., Wolff J.A., Simon G., Vacek M., Jue D.L., Johnson M.H. Hemoglobin Presbyterian: beta108 (G10) asparagine leads to lysine. A hemoglobin variant with low oxygen affinity. FEBS Lett. 92:1978;53-56.
27. Looker D., Abbott-Brown D., Cozart P., Durfee S., Hoffman S., Mathews A.J., Miller-Roehrich J., Shoemaker S., Trimble S., Fermi G., et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature. 356:1992;258-260.
28. Rioux F., Petitclerc E., Audet R., Drapeau G., Fielding R.M., Marceau F. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 24:1994;229-237.
29. Rioux F., Drapeau G., Marceau F. Recombinant human hemoglobin (rHb1.1) selectively inhibits vasorelaxation elicited by nitric oxide donors in rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 25:1995;587-594.
30. Chakder S., Rosenthal G.J., Rattan S. In vivo and in vitro influence of human recombinant hemoglobin on esophageal function. Am. J. Physiol. 268:1995;G443-G450.
31. Rattan S., Rosenthal G.J., Chakder S. Human recombinant hemoglobin (rHb1.1) inhibits nonadrenergic noncholinergic (NANC) nerve-mediated relaxation of internal anal sphincter. J. Pharmacol. Exp. Ther. 272:1995;1211-1216.
32. Zuckerman S.H., Doyle M.P., Gorczynski R., Rosenthal G.J. Preclinical biology of recombinant human hemoglobin, rHb1.1. Artif. Cells Blood Substit. Immobil. Biotechnol. 26:1998;231-257.
33. Viele M.K., Weiskopf R.B., Fisher D. Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology. 86:1997;848-858.
34. Doherty D.H., Doyle M.P., Curry S.R., Vali R.J., Fattor T.J., Olson J.S., Lemon D.D. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin [see comments]. Nat. Biotechnol. 16:1998;672-676.
35. Conover C.D., Linberg R., Gilbert C.W., Shum K.L., Shorr R.G. Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models. Artif. Organs. 21:1997;1066-1075.
36. Conover C.D., Gilbert C.W., Shum K.L., Shorr R.G. The impact of polyethylene glycol conjugation on bovine hemoglobin's circulatory half-life and renal effects in a rabbit top-loaded transfusion model. Artif. Organs. 21:1997;907-915.
37. Nucci M.L., Shorr R.G. PEG-Hemoglobin. Drugs of the Future. 21:1996;29-32.
38. Conover C.D., Malatesta P., Lejeune L., Chang C.L., Shorr R.G. The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG-Hb) in a conscious porcine model. J. Invest. Med. 44:1996;238-246.
39. Nakai K., Ohta T., Sakuma I., Akama K., Kobayashi Y., Tokuyama S., Kitabatake A., Nakazato Y., Takahashi T.A., Sadayoshi S. Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins. J. Cardiovasc. Pharmacol. 28:1996;115-123.
40. Conover C.D., Lejeune L., Shum K., Gilbert C., Shorr R.G. Physiological effect of polyethylene glycol conjugation on stroma-free bovine hemoglobin in the conscious dog after partial exchange transfusion. Artif. Organs. 21:1997;369-378.
41. Baldwin A.L., Wilson L.M., Valeski J.E. Ultrastructural effects of intravascularly injected polyethylene glycol-hemoglobin in intestinal mucosa. Am. J. Physiol. 275:1998;H615-H625.
42. Nozue M., Lee I., Manning J.M., Manning L.R., Jain R.K. Oxygenation in tumors by modified hemoglobins. J. Surg. Oncol. 62:1996;109-114.
43. Ali A.C., Mihas C.C., Campbell J.A. Interferences of o-raffinose cross-linked hemoglobin in three methods for serum creatinine. Clin. Chem. 43:1997;1738-1743.
44. Hsia J.C. O-raffinose polymerized hemoglobin as a red blood cell substitute [Abstract]. Biomater. Artif. Cells Immobil. Biotechnol. 19:1991;402.
45. Thompson A., McGarry A.E., Valeri C.R., Lieberthal W. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J. Appl. Physiol. 77:1994;2348-2354.
46. Lieberthal W., Fuhro R., Freedman J.E., Toolan G., Loscalzo J., Valeri C.R. O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J. Pharmacol. Exp. Ther. 288:1999;1278-1287.
47. Hsia J.C., Song D.L., Er S.S., Wong L.T., Keipert P.E., Gomez C.L., Gonzales A., Macdonald V.W., Hess J.R., Winslow R.M. Pharmacokinetic studies in the rat on a o-raffinose polymerized human hemoglobin. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;587-595.
48. C. Lou, G. BS, Pharmacokinetic profile of HemoLink™, An o-Raffinose cross-linked human hemoglobin, in volunteers [Article]. Anesthesiology 89 (1998) Supplement.
49. C.D.M. Mazer, D. BS, Safety and Efficacy of HemoLink™ during cardiopulmonary bypass. Anesthesiology 89 (1998) Supplement.
50. Kida Y., Iwata S., Gyoutoku Y., Aikou A., Yamakawa T., Nishi K. Vascular responsiveness to various vasoactive substances after exchange transfusion with pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) solution in anesthetized rats. Artif. Organs. 15:1991;5-14.
51. Yamakawa T., Miyauchi Y., Nishi K. Effects of pyridoxalated hemoglobin polyoxyethylene conjugate and stroma-free hemoglobin on cardiac function in isolated rat heart. Artif. Organs. 14:1990;208-217.
52. Kida Y., Maeda M., Iwata S., Iwashita Y., Goto K., Nishi K. Effects of pyridoxalated hemoglobin polyoxyethylene conjugate and other hemoglobin-related substances on arterial blood pressure in anesthetized and conscious rats. Artif. Organs. 19:1995;117-128.
53. Brady A.J., Warren J.B., Poole-Wilson P.A., Williams T.J., Harding S.E. Nitric oxide attenuates cardiac myocyte contraction. Am. J. Physiol. 265:1993;H176-H182.
54. Sprung J., Mackenzie C.F., Barnas G.M., Williams J.E., Parr M., Christenson R.H., Hoff B.H., Sakamoto R., Kramer A., Lottes M. Oxygen transport and cardiovascular effects of resuscitation from severe hemorrhagic shock using hemoglobin solutions. Crit. Care Med. 23:1995;1540-1553.
55. Snyder S.H. Nitric oxide: first in a new class of neurotransmitters. Science. 257:1992;494-496.
56. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:1991;109-142.
57. Feola M., Simoni J., Fishman D., Tran R., Canizaro P.C. Biocompatibility of hemoglobin solutions. I. Reactions of vascular endothelial cells to pure and impure hemoglobins. Artif. Organs. 13:1989;209-215.
58. Matsushita M., Yabuki A., Malchesky P.S., Harasaki H., Nose Y. In vivo evaluation of a pyridoxylated-hemoglobin-polyoxyethylene conjugate. Biomater. Artif. Cells Artif. Organs. 16:1988;247-260.
59. Matsushita M., Yabuki A., Chen J.F., Takahashi T., Harasaki H., Malchesky P.S., Iwashita Y., Nose Y. Renal effects of a pyridoxalated-hemoglobin-polyoxyethylene conjugate solution as a blood substitute in exchange transfusions. ASAIO Trans. 34:1988;280-283.
60. Takahashi T., Iwasaki K., Malchesky P.S., Harasaki H., Emoto H., Goldcamp J.B., Matsushita M., Nose Y., Rolin H.d., Hall P. Effects of single-dose infusion of pyridoxalated-hemoglobin-polyoxyethylene conjugate solution on canine renal function. Artif. Organs. 15:1991;462-473.
61. Yabuki A., Matsushita M., Malchesky P.S., Iwasaki K., Iwashita Y., Nose Y. In vitro evaluation of a pyridoxalated hemoglobin polyoxyethylene conjugate in reversing cell sickling. ASAIO Trans. 34:1988;773-777.
62. Takahashi T., Iwasaki K., Malchesky P.S., Harasaki H., Matsushita M., Nose Y., Rolin H.d., Hall P.M. Renal effects of multiple infusion of pyridoxalated-hemoglobin-polyoxyethylene conjugate (PHP) solution in dogs. Artif. Organs. 17:1993;153-163.
63. Noone R.B. Jr., Mythen M.G., Vaslef S.N. Effect of alpha(alpha)-cross-linked hemoglobin and pyridoxalated hemoglobin polyoxyethylene conjugate solutions on gastrointestinal regional perfusion in hemorrhagic shock. J. Trauma. 45:1998;457-469.
64. Bone H.G., Schenarts P.J., Fischer S.R., McGuire R., Traber L.D., Traber D.L. Pyridoxalated hemoglobin polyoxyethylene conjugate reverses hyperdynamic circulation in septic sheep. J. Appl. Physiol. 84:1998;1991-1999.
65. Bone H.G., Fischer S.R., Schenarts P.J., McGuire R., Traber L.D., Traber D.L. Continuous infusion of pyridoxalated hemoglobin polyoxyethylene conjugate in hyperdynamic septic sheep. Shock. 10:1998;69-76.
66. Nishida J., McCuskey R.S., McDonnell D., Fox E.S. Protective role of NO in hepatic microcirculatory dysfunction during endotoxemia. Am. J. Physiol. 267:1994;G1135-G1141.
67. Pastor C.M., Billiar T.R. Regulation and functions of nitric oxide in the liver in sepsis and inflammation. New Horiz. 3:1995;65-72.
68. Hughes G.S. Jr., Francome S.F., Antal E.J., Adams W.J., Locker P.K., Yancey E.P., Jacobs E.E. Jr. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J. Lab. Clin. Med. 126:1995;444-451.
69. Vlahakes G.J., Lee R., Jacobs E.E. Jr., LaRaia P.J., Austen W.G. Hemodynamic effects and oxygen transport properties of a new blood substitute in a model of massive blood replacement. J. Thorac. Cardiovasc. Surg. 100:1990;379-388.
70. Lee R., Neya K., Svizzero T.A., Vlahakes G.J. Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J. Appl. Physiol. 79:1995;236-242.
71. Teicher B.A., Schwartz G.N., Alvarez Sotomayor E., Robinson M.F., Dupuis N.P., Menon K. Oxygenation of tumors by a hemoglobin solution. J. Cancer Res. Clin. Oncol. 120:1993;85-90.
72. Kasper S.M., Walter M., Grune F., Bischoff A., Erasmi H., Buzello W. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth. Analg. 83:1996;921-927.
73. Kasper S.M., Grune F., Walter M., Amr N., Erasmi H., Buzello W. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth. Analg. 87:1998;284-291.
74. Hughes G.S. Jr., Antal E.J., Locker P.K., Francom S.F., Adams W.J., Jacobs E.E. Jr. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit. Care Med. 24:1996;756-764.
75. Hughes G.S. Jr., Yancey E.P., Albrecht R., Locker P.K., Francom S.F., Orringer E.P., Antal E.J., Jacobs E.E. Jr. Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin. Pharmacol. Ther. 58:1995;434-443.
76. Gonzalez P., Hackney A.C., Jones S., Strayhorn D., Hoffman E.B., Hughes G., Jacobs E.E., Orringer E.P. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J. Invest. Med. 45:1997;258-264.
77. J. Levy, American Heart Association 71st scientific sessions. Dallas, Texas, USA. November 8-11, 1998. Abstracts. Circulation 98 (1998) I-132.
78. Gould S.A., Moore E.E., Hoyt D.B., Burch J.M., Haenel J.B., Garcia J., DeWoskin R., Moss G.S. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery [see comments]. J. Am. Coll. Surg. 187:1998;113-120. Discussion 120-2.
79. Gould S.A., Moss G.S. Clinical development of human polymerized hemoglobin as a blood substitute. World J. Surg. 20:1996;1200-1207.
80. Keipert P.E., Gomez C.L., Gonzales A., MacDonald V.W., Hess J.R., Winslow R.M. Diaspirin cross-linked hemoglobin: tissue distribution and long-term excretion after exchange transfusion. J. Lab. Clin. Med. 123:1994;701-711.
81. Johnson J.L., Moore E.E., Offner P.J., Haenel J.B., Hides G.A., Tamura D.Y. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am. J. Surg. 176:1998;612-617.
82. Gould S.A., Sehgal L.R., Rosen A.L., Sehgal H.L., Moss G.S. The efficacy of polymerized pyridoxylated hemoglobin solution as an O2 carrier [see comments]. Ann. Surg. 211:1990;394-398.
83. Krishna M.C., Samuni A., Taira J., Goldstein S., Mitchell J.B., Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and mechanism. J. Biol. Chem. 271:1996;26018-26025.
84. D'Agnillo F., Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties [see comments]. Nat. Biotechnol. 16:1998;667-671.
85. Razack S., D'Agnillo F., Chang T.M. Crosslinked hemoglobin-superoxide dismutase-catalase scavenges free radicals in a rat model of intestinal ischemia-reperfusion injury. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:1997;181-192.
86. Rohlfs R.J., Bruner E., Chiu A., Gonzales A., Gonzales M.L., Magde D., Magde M.D. Jr., Vandegriff K.D., Winslow R.M. Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide. J. Biol. Chem. 273:1998;12128-12134.
87. Przybelski R.J., Daily E.K., Kisicki J.C., Mattia-Goldberg C., Bounds M.J., Colburn W.A. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit. Care Med. 24:1996;1993-2000.
88. Doyle M.P., Apostol I., Kerwin B.A. Glutaraldehyde modification of recombinant human hemoglobin alters its hemodynamic properties. J. Biol. Chem. 274:1999;2583-2591.
89. Winslow R.M., Gonzales A., Gonzales M.L., Magde M., McCarthy M., Rohlfs R.J., Vandegriff K.D. Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. J. Appl. Physiol. 85:1998;993-1003.
90. Vogel W.M., Cassidy G., Valeri C.R. Effects of o-raffinose-polymerized human hemoglobin on coronary tone and cardiac function in isolated hearts. Biomater. Artif. Cells Immobil. Biotechnol. 20:1992;673-677.
91. Hsia J.C., Song D.L., Er S.S., Wong L.T.L., Keipert P.E., Gomez C.L., Gonzales J.R., MacDonald V.W., Winslow R.M. Pharmacokinetic studies on a Raffinose-polymerized human hemoglobin in the rat. Biomater. Artif. Cells Immobil. Biotechnol. 19:1991;401.